

1 **Title:**

2 **Enhancing the Implementation Process of Trachoma Interventions Using**
3 **Design Thinking Approach in Tanzania: A research protocol to identify the**
4 **novel strategy in a Trachoma Persistent District.**

5 **Authors:**

6 ¶Innocent Semali^{1a} innocent.semali@hkmu.ac.tz ; ¶George Kabona²
7 drkabona@yahoo.com; ¶Yohanna Mshalla¹ yohana.mashalla@hkmu.ac.tz ; ¶Columba
8 Mbekenga¹ columba.mbekenga@hkmu.ac.tz; ¶Deodatus Kakoko³
9 deodatuskakoko@gmail.com; ¶Adelah Sariah¹ adellah.sariah@hkmu.ac.tz ; ¶Ambakise
10 Mhiche² ambakisyekuyokwa@gmail.com; ¶Moshi Ntabaye¹ moshi.ntabaye@hkmu.ac.tz;
11 ¶Godwin Ndosi¹ godwin.ndossi@hkmu.ac.tz; &Alex Mwijage³
12 mwijagealexander2014@yahoo.com; &Anitha Kemi⁴ kemianita@gmail.com

13

14 Affiliation of authors:

- 15 1; Hubert Kairuki Memorial University
16 2. Trachoma Control Program Ministry of Health
17 3. Muhimbili University of Health and Allied Sciences.

18 Submitting author

19 ^a corresponding author email innocent.semali@hkmu.ac.tz

20 contribution of authors:

21 ¶¶These authors contributed equally

22 &These authors also contributed equally.

23 Acknowledgement: We would like to express my profound and sincere gratitude to Bill and

24 Melinda Foundation for accepting to fund this protocol

25 **Summary**

26 **Background:** Trachoma is among the major causes of blindness affecting approximately 8 million
27 people globally. The disease is most prevalent in rural populations with poor access to clean
28 water, health care, and poor environmental hygiene. Current effective efforts to curb the disease
29 include SAFE (surgery, antibiotic treatment, facial hygiene and environmental change)
30 interventions which have shown evidence of real-world effectiveness in the control of trachoma.
31 With the use of SAFE, WHO, governments and other stakeholders vowed to eliminate trachoma
32 by 2020. Though by 2020 people at risk of trachoma had dropped by 90%, few countries including
33 Tanzania were yet to achieve the 2020 goal. Tanzania remained with ten districts highly endemic
34 to trachoma despite regular implementation of the SAFE interventions, suggesting wicked
35 trachoma implementation problems that demand taking different approach to address its
36 complexity. Such an approach will be design thinking to enable identification of effective novel
37 SAFE implementation strategy that is human centered that enables the understanding of those at
38 risk of Trachoma consequently improving access and the utilization of SAFE interventions.

39 **Aim:** This study aims to gain an understanding of the challenges experienced by communities to
40 access SAFE interventions in the Trachoma endemic areas including stakeholders enabling the
41 understanding of their perceptions, feelings, and behaviors regarding the trachoma
42 implementation interventions. Consequently enabling the designing of effective and innovative
43 human-centered approaches to enhance the implementation of SAFE strategies in the endemic
44 communities.

45 **Methods:** the study will be implemented in two villages in Manyara region where Trachoma is
46 persistent despite several rounds of mass drug administration (MDA) over several years. It is a
47 design think approach with five phases iteratively. The study will be in two main phases starting
48 with rapid assessment which will employ Trachoma implementation documents and qualitative

49 interviews of selected stakeholders. Its aim will be to understand the ongoing implementation of
50 SAFE interventions performance, promoting and also impeding contexts. Phase two will then
51 follow and will employ five-phased design thinking approach to comprehend the SAFE target
52 population. The design thinking will start with empathy phase, followed with define, ideation,
53 prototyping and finally testing the resulting innovations. As an iterative process each of the
54 subsequent phases will be informed by the previous phase.

55 The rapid assessment will identify challenges that need exploration, refine research methods and
56 tools, and finalize selection of teams and stakeholders to be involved in the study. The empathy
57 phase will involve obtaining information to gain a deeper understanding of the SAFE target
58 population. Data collection methods during this phase will include qualitative interview,
59 observations, workshops, taking photos and videos. The define phase will involve analyzing
60 information obtained from the empathy phase to develop actionable problem statements that will
61 provide guidance to the next phases. During the ideation phase, in collaboration with the SAFE
62 target population and stakeholders, the research team will formulate possible solutions to address
63 each of the identified problem statements from the define phase. In the prototype phase, the
64 researchers, the SAFE target population and other stakeholders will work together to create an
65 innovative product identified from possible solutions in the ideation phase, which has a high
66 probability of solving SAFE implementation challenges. The final test phase will involve testing
67 the innovative interventions identified in the prototype phase to assess desirability, feasibility,
68 and viability among the SAFE target population follow-up interviews, and observations. A product
69 with such with such qualities of desirability, feasibility, and viability of the innovative product would
70 then passed for future roll out.

71 Ethical clearance will be obtained from the Hubert Kairuki Memorial University (HKMU)
72 Institutional Research Ethics Committee and permission to conduct the study will be obtained
73 from relevant local authorities. Informed consent will be sought from local authorities and

74 participants before any data collection round. Anonymity and confidentiality will be observed
75 during and after data collection round.

76 Author summary.

77 Trachoma is leading causes of blindness affecting approximately 8 million people globally. The
78 disease is most prevalent in rural populations with poor access to clean water, health care, and
79 poor environmental hygiene. It is an eye infection caused by Chlamydia trachomatis which is
80 transmitted from eye to eye through direct or indirect transfer of eye and nose discharges of
81 infected person to uninfected persons. Most of the infection among children 1-9 years and their
82 mothers, however blindness occurs among those 20 years and above. Efforts to control
83 trachoma were intensified in 1996 when Global Elimination of Trachoma by 2020 (GET2020)
84 was declared through surgery for people with eye trachomatous trichiasis, mass drug
85 administration for those at risk of infection living in endemic districts, face washing and
86 adequate environmental hygiene with acronym SAFE.

87 Assessments at the end of the time frame in 2020 there was around 92% reduction in the
88 number of people at risk of Trachoma. Thus, about ten percent of the countries had not
89 achieved the goal including Tanzania where ten districts were experiencing Trachoma
90 recrudescence or persistence as global problem despite several rounds of mass administration
91 of Azithromycin. Thus, there was an implementation failure which by using design thinking
92 approach will lead to identification of an innovative strategy that will address this implementation
93 problem. It is funded by Bill and Melinda foundation and ethical clearance will be obtained from
94 the Hubert Kairuki Memorial University in Dar es Salaam Tanzania.

95 **Implementation gap**

96 Trachoma is contagious disease of the eyes that spread through contact with the eyes, eyelids,
97 and the secretions from the nose or throat of an infected person and accounting for about 8 million

98 cases of global blindness[1]. World Health Organization grades Trachoma into five stages starting
99 with active infectious stage the Trachomatous inflammation also known as follicular (TF). The
100 second stage is Trachomatous inflammation intense (TI) and the third stage is Trachomatous
101 scarring (TS) which is the presence of scarring in tarsal conjunctiva. The fourth stage is
102 Trachomatous trichiasis (TT) and the fifth and last stage is Corneal Opacity (CO) characterized
103 by distorted vision including blindness[2]. Globally, about 84 million people are suffering from
104 active Trachoma, while 7.5 million have trichiasis and 8 million are blind and are in Sub-Saharan
105 Africa.

106

107 Blinding trachoma remains a significant public health problem despite concerted efforts to control
108 it dating centuries back. Such efforts include evidence of antibiotic effectiveness in the 1950s that
109 was further corroborated in 1990 when Azithromycin was verified as highly effective against
110 trachoma[3]. Current intervention developments include the promotion of novel interventions
111 whose main constituent included a synergistic strategy that was given the acronym SAFE
112 meaning S (surgery) for tertiary prevention of eye deformities, and A (antibiotic treatment) as
113 secondary prevention, F (facial hygiene) and E (environmental change) which focus on
114 environmental hygiene[4]. SAFE, the integrated strategy was further field-tested in several
115 countries revealing a highly significant effect in the control of trachoma [5, 6]. Global consistency
116 of the real-world effectiveness of SAFE was also positively corroborated by evidence that
117 emerged from China where before the 1980s trachoma prevalence ranged from 50% to 90% but
118 after the mid-1980s which coincided with the rollout of integrated SAFE strategies, trachoma
119 prevalence dropped to less than 10%[7]. In 1996 WHO with partners jointly declared to achieve
120 Global Elimination of Trachoma by 2020 (GET 2020), through the global alliance partnerships
121 and use of Azithromycin in the **SAFE** trachoma control strategy)[8].

122 Following SAFE real-world effectiveness multiple stakeholders and Governments ratified and
123 embarked on the goal of eliminating trachoma as a public health problem by 2020. Consequently,
124 by 2020, the population at risk of trachoma had declined by 90% while out of 38 countries endemic
125 to trachoma, 27 countries including Tanzania remained endemic despite the concerted SAFE
126 strategies and the expiration of the timeframe [9]. Thus, currently in Tanzania Trachoma remains
127 geographically clustered among some of the difficult to reach populations[10]. Failure to achieve
128 the 2020 goal in Tanzania and some countries, signaled wicked implementation problems with
129 compelling need to comprehend the implementation barriers and contexts of implementing SAFE
130 trachoma control in the remaining countries including Tanzania. This will enable Tanzania adopt
131 more versatile implementation promotion methods to facilitate achieving the next goal defined in
132 the roadmap 2021-2030. This sets 2030 as the new target timeframe for the global elimination of
133 trachoma in those countries[11].

134 Resetting the 2020 timeframe coincided with the SDG contexts whose one of the critical aim
135 included to increase knowledge through research, and extend partnerships to increase service
136 coverage, specifically on facial cleanliness and environmental improvement to reduce trachoma
137 transmission[12]. Thus some of the implementation hurdles could be solved with innovative
138 research strategies that will successfully address the wicked implementation challenges. In
139 response to these issues, HKMU responded to the Bill and Melinda Gates Foundation's (BMGF)
140 call for a research proposal addressing implementation challenges affecting NTDs including
141 Trachoma. HKMU has been awarded BMGF grant to enable making a contribution towards
142 addressing the Trachoma implementation challenges prevailing in Tanzania. HKMU will jointly
143 work with the Ministry of Health (MoH) and the Muhimbili University of Health and Allied Sciences
144 (MUHAS) and the University of Dar es Salaam (UDSM) to undertake this awarded research
145 project to create a novel intervention strategy to facilitate overcoming the Trachoma intervention

146 implementation hurdles. Thus enhancing the implementation of Trachoma interventions in an
147 area where there is Trachoma persistence despite the regular control efforts including MDAs.

148 A recent Lancet editorial on the WHO NTD Roadmap 2012–2020 observed that though 600
149 million people benefited from existing Trachoma interventions, making further progress will
150 require focusing on the needs and rights of marginalized people in low-income countries[13]. This
151 further asserts that the problem being experienced in the implementation of Trachoma
152 interventions is wicked as it relates to poverty, ignorance, health system, communities, cultures,
153 and politics among others. As a wicked problem, it will require an implementation research and
154 empathic approaches to enable making further progress in the implementation of Trachoma
155 interventions. It will enable understanding communities, their desires, their needs, perceptions,
156 and technical feasibility of SAFE leading to the creation of human-centered innovative
157 intervention strategy to overcome the prevailing Trachoma implementation hurdles. Henceforth,
158 an empathic understanding of the SAFE target populations shall enable successes in addressing
159 the wicked implementation challenges in the process of Trachoma control.

160 **Problem statement**

161 In 1999, Tanzania successfully piloted mass administration of Azithromycin (MDA) in the SAFE
162 strategy in a few districts[14]. The evidence justified SAFE implementation in 43 trachoma
163 endemic districts identified from the 2002-2004 baseline surveys of 50 districts that had TF
164 prevalence $\geq 10\%$ according to WHO guidelines for MDA. Subsequent surveys including those
165 from 2012 to 2014 among 31 districts mapped as part of the Global Trachoma Mapping Project
166 (GTMP), MDA was rolled out to 95 districts endemic to trachoma[15]. These were followed by
167 the NTD program impact survey in 2018 which revealed that 63 out of the 71 endemic districts
168 had attained an elimination threshold of TF $<5\%$ [16]. Thus, persistent TF and recrudescence TF
169 are major end-game challenges in attaining trachoma elimination by 2030 a timeframe set after
170 2020.

171 Following the concerted SAFE strategies, recrudescence and persistence problems were first
172 identified in 2017 and become more established over the 5 years that followed in four districts
173 namely; Longido, Ngorongoro, Kiteto and Simanjiro which had not attained the TF elimination
174 threshold despite multiple cycles of MDA (ranged 8-12 rounds) [17]. In addition, recrudescence TF
175 was observed in 3 districts: Kongwa, Chamwino, and Mpwapwa which also had been
176 implementing MDA regularly since 1999 to date. Sustained recrudescence and or persistence is
177 a reversal of the gains realized by the ongoing investments, further escalating morbidity and
178 disability due to trachoma, limiting school enrollment, poor school outcome and also increased
179 blindness among adults further lowers the productivity while increasing dependence ratio.
180 Consequently, enhancing the poverty cycle and thus compromise the process towards achieving
181 the Sustainable Development Goals by 2030.

182 It is indeed important to reckon that Trachoma control has reached an endgame challenge
183 characterized by the persistence and or recrudescence consequent to stalled uptake of the
184 standard highly effective SAFE interventions in isolated implementation sites. In response, there
185 has been an observation to undertake in-depth studies to understand in detail the determinants
186 of the observed wicked challenges[9]. The determinants are multi-levels and multi-sectoral
187 including difficult-to-reach communities and are linked with extreme poverty; environmental
188 factors, beliefs and traditions, economic, and health system where many fail to disentangle.
189 Therefore, implementation research will be adopted to study the problem. In this study, we
190 describe a protocol of implementation research in the contexts of design thinking funded by the
191 Bill and Melinda Gates Foundation through Grant Agreement vide Investment reference ID INV-
192 046340. As stated earlier Jointly implemented by Hubert Kairuki Memorial University (HKMU), the
193 Neglected Tropical Diseases Program (NTDs) from the Ministry of Health - Dodoma, Tanzania
194 and Muhimbili University of Health and Allied Sciences (MUHAS).

195 **Justifications for the implementation problem**

196 The Tanzania Ministry of Health is seeking solutions to the wicked implementation challenges
197 toward achieving the elimination of trachoma as a public health problem by 2030. Most of the
198 remaining districts with persistent or recrudescence TF prevalence above 5% are nomadic
199 populations. Hence the study will be carried out looking for innovative strategies that will
200 facilitate implementation of the Trachoma control interventions to increase the uptake of the
201 control interventions among those vulnerable nomadic population. Thus the study will revisit the
202 implementation strategies among the communities and related contexts in order to gain an
203 empathic understanding of the communities and contexts to create novel interventions that will
204 enable overcoming the wicked implementation problems and consequently achieve effective
205 and efficient strategy for elimination of Trachoma by 2030.

206 **Study hypothesis**

207 After more than 20 years of SAFE including regular MDA interventions, trachoma is still endemic
208 in 9 districts in Tanzania most of which are clustered within the nomadic dry belt of Arusha,
209 Manyara and Dodoma regions. It is postulated that the limited SAFE intervention implementation
210 success is due to wicked implementation problems emanating from the complexity in intervention
211 design, implementation and contexts(social, cultural, health systems and economic). On that
212 account. such complexity will require using a Design Thinking approach which will enable
213 generating data to facilitate empathic understanding of the nomadic community, and stakeholder's
214 perceptions, access, thinking and their behaviors towards the Trachoma intervention
215 implementation process. As a consequence, it will enable the acquisition of a human-centered
216 strategy which shall enhance the development of an innovative intervention strategy that will be
217 efficacious to hasten the implementation processes of SAFE among those communities left
218 behind.

219 **Goal**

220 The goal is to generate empathic data from the target populations and stakeholders that will
221 enable the design and adoption of an innovative strategy to facilitate overcoming the wicked
222 challenges in the implementation process of SAFE trachoma interventions among the nomadic
223 community in Tanzania.

224 Specific objectives will be aligned to each of the phases of Design Thinking namely *empathy,*
225 *definition, ideation, prototyping and testing.*

226 **Specific objectives:**

- 227 1. To conduct rapid assessment and acclimatization to the current SAFE implementation and
228 contexts to the control of Trachoma in the selected study areas.
- 229 2. To generate empathic, multidimensional information to enable empathic understanding of
230 the SAFE target populations and stakeholders' in respect to the implementation of the
231 SAFE Trachoma interventions in the respective area.
- 232 3. To conduct empathy mapping to enable the visualization of the empathy data into
233 thoughts, feelings, and actions of the SAFE target population in order give to get a better
234 understanding of the SAFE target population SAFE experiences.
- 235 4. To define the core SAFE implementation problems from the empathy data and pitching
236 the problem statement from the perception of the SAFE target population correctly to
237 generate a variety of specific problem statement questions for processing in the next
238 ideation phase.
- 239 5. To openly and jointly researchers with SAFE target population and stakeholders jointly in
240 this ideation phase deliberate on the problem statements from the define phase to
241 generate priority solutions that that will then be submitted to prototype phase as potential
242 solutions to the SAFE implementation challenges.

- 243 6. To turn the SAFE priority possible solutions from the ideation phase into SAFE solution
244 prototypes or something tangible which can be tested among real SAFE users. It is to
245 identify solutions that have a high likelihood of solving SAFE implementation obstacles as
246 being experienced by the SAFE target population.
- 247 7. To test expose the proposed novel SAFE intervention prototype to the SAFE target
248 population for the first time and determine its desirability, feasibility, and viability as a
249 measure that it be effective to address the SAFE implementation problems.
- 250 8. To submit proposal to evaluate effectiveness of the novel SAFE implementation
251 intervention strategy among SAFE target population in a wider scale.

252 **Literature review**

253 Trachoma remains an important public health problem that in the 19th century and much earlier
254 affected all countries. Its prevalence ranged between 50% and 90% and accounted for a
255 significant proportion of preventable blindness[3, 18]. The high prevalence of Trachoma was
256 sustained by the high level of poverty, poor environmental sanitation and poor personal hygiene.
257 It was also fueled and sustained by the interaction effects of people movements, wars and
258 occupation of military troops as well as migration from rural areas to urban and between
259 countries [18]. However, by the mid-1990s, trachoma had been eliminated in Europe and most
260 of North America because of significant developments that led to improved sanitation, water
261 availability and treatment [19].

262 That notwithstanding, trachoma remained a problem affecting 150 million people mostly children
263 and also among whom 6 million were blind in 48 countries mostly in Africa, Asia and some of
264 South America[20, 21]. The highest prevalence of trachoma was reported in countries South of
265 Sahara including Sudan and Ethiopia and, in some areas, trachoma was hyperendemic as the
266 prevalence among children 1-9 years was more than 50% while about a fifth of the adults was

267 found to have high scarring trachoma[20]. To address the remaining burden of trachoma, in 1997
268 the World Health Organization announced a strategy to eliminate trachoma as a cause of
269 blindness by the year 2020.

270 **Causal agent and natural history of Trachoma**

271 Chlamydia trachomatis is the causal agent of Trachoma disease, a leading cause of blindness
272 currently estimated at 8 million cases globally[22, 23]. Chlamydia trachomatis, is an obligate
273 intracellular bacterium isolated for the first time in 1958 despite the existence of the disease for
274 centuries[18]. It is both directly and indirectly transmitted from one person to the other through
275 eye to eye during close contact and also spread by fingers. An indirect spread involves sharing
276 of fomites, clothes, or even playing tools and particular species of flies which also play significant
277 role in the transmission [24, 25]. The disease also commonly occurs in clusters of age, gender,
278 villages, hamlets, households, or even bedrooms and residential areas[26, 27] Trachoma natural
279 history occurs in two distinct phases, phase one or “active phase” occurs largely among children
280 1-9 years followed by phase two that occurs two to three decades later among adults also known
281 as cicatricial (scarring structural damage). Initially, the early phase is commonly found in children
282 manifesting as recurrent chronic follicular conjunctivitis[28-30]. As recurrent chronic follicular
283 conjunctivitis persists and becomes more severe it leads to conjunctival scarring which results in
284 shortening and distortion of the eyelid. Consequently, the scarring of the eyelids and shortening
285 causes inward-turning, an effect referred to as entropion[31]. The in-turned eyelids causes the
286 eyelashes to come into contact with the eyeball resulting in trichiasis. At this stage, the eyelashes
287 scratch the cornea resulting in scarring that leads to corneal opacification later manifesting as
288 blindness or diminished vision which is abated by surgical intervention.

289 **Epidemiology and risk factors for Trachoma**

290 Recent estimates in 2022 reported that populations in areas that warranted intense SAFE
291 interventions had declined by 90% while those with Trachomatous trichiasis had declined by 80%
292 revealing very significant gains consequent to the global, national and stakeholders efforts toward
293 the control of Trachoma[32]. This reflects an estimate of 125 million people are at risk of
294 trachoma blindness while 1.9 million are estimated to be blind or have visual impairment due to
295 Trachoma[33]. These current global figures reflect the gains from various global and national
296 efforts to eradicate the disease when compared to 1995 estimates revealed that 150 million
297 people were affected, in 48 countries, and 6 million were blind[3, 20].

298 As stated above, the infection and prevalence of active Trachoma disease starts early in
299 childhood peaking among children less than five years, declining gradually to a very low
300 percentage among those 21 to 40 years[30, 34]. On the other hand, the prevalence of scarring
301 trachoma (trichiasis) increases gradually from 1.0% among children under five years to 38%
302 among those 40 years and older in endemic areas. It is therefore agreed that young children
303 constitute a reservoir for trachoma with direct effects on those in close proximity especially
304 mothers and other children. Hence this could explain the high risk of trachoma estimated at 3.9
305 more likely among women compared to males [28]. The phenomenon is further supported by the
306 results of a systematic review which observed that about three-quarter of corneal blindness and
307 trichiasis occurs among women compared to men [35]. Hence, women constitute a high-risk
308 group perpetuated by their responsibilities as caregivers among families calling for concerted
309 efforts to enhance access to SAFE strategies among women thus offsetting this gender inequality.
310 In addition, the likelihood of trachoma infection increases with the presence of nasal and ocular
311 discharges among children and having more than two children in a household [36].

312 Other risk factors for trachoma include environmental factors supported by the observation that
313 that living in a household that consumed 60 liters of water per day significantly lowered the
314 likelihood of being infected with trachoma[37]. Thus, easy access to water would contribute to

315 frequent washing which would interrupt the transmission dynamics of the causative agent from
316 those infected to those un-infected. This was also corroborated by the findings that those who
317 used less than two liters of water for face washing per day had an increased risk of trachoma
318 infection. The role of water scarcity and endemicity of trachoma is also corroborated by the
319 observation that the risk of trachoma diseases has been reduced significantly as water sources
320 increased [7].

321 Furthermore, a significant increase in the risk of trachoma was observed where environmental
322 hygiene was poor which included the presence of liquid waste around the house and also the
323 presence of fecal matter in the household proximity [3]. In addition, the risk was significantly
324 elevated where personal hygiene was poor due to lack of face and hands washing in addition to
325 the presence of flies around children's faces [36]. Also, poor environmental hygiene, the location
326 of the toilet within the family setup was associated significantly with an increased risk of trachoma
327 if it was less than 10 meters away from the living house.

328 **Interventions to control, Trachoma**

329 While households should always have some optimal amount of water to ensure that life goes on,
330 it will indeed be wise with the same water per capita use economies of scale approach as an
331 interim measure to enhance facial cleanliness in households and especially children and women.
332 That notwithstanding, interventions to control trachoma are complex and should include focusing
333 on the environment, personal hygiene as well as the trachoma causative agent. Following the
334 1996 Global Scientific meeting to control Trachoma, the World Health Organization WHO Alliance
335 for the Global Elimination of Trachoma by 2020 also referred to as WHO GET2020[8] was
336 initiated. As a prerequisite to achieving this goal, WHO adopted the SAFE strategy to enhance
337 the trachoma transmission dynamic[38] Systematic application of SAFE strategy in China and
338 some other countries recorded a significant prevalence decline among children 1 to 9 years

339 (children₁₋₉) from 55% in early 1980 to less than 5% in 2014, in addition trichiasis declined to less
340 than 1 percent [7]. The decline provided evidence that the SAFE strategy was effective and highly
341 capable to achieve the WHO's ultimate goal of eliminating trachoma by 2020.[38]

342 **Monitoring progress in Trachoma control**

343 Also indisputable evidence exists supporting the multi-country rollout of the SAFE strategy among
344 the 36 countries that were endemic to trachoma in the late 1990s and early 2000s [9]. The success
345 of the strategy was monitored using the WHO's ultimate intervention goals and indicators toward
346 achieving the elimination of trachoma as a public health problem [39]. The following are the
347 indicators that include mass drug administrative (MDA) frequency based on prevalence data
348 from community-based on regular trachoma surveillance among children between the ages of
349 1–9 years (Children₁₋₉):

- 350 1. SAFE implementation in a country or a geographical area must reduce the number of people
351 with trichiasis through surgery to less than 0.2 percent among people aged 15 years and
352 above in a district.
- 353 2. Also, each country must reduce the number of cases of active trachoma (TF) in children of
354 ages 1 to 9 years (children₁₋₉) to less than 5 percent of the population of children in any district
355 using Azithromycin to be declared that a country has eliminated trachoma as a public health
356 problem. Furthermore the following is the frequency and duration of azithromycin mass
357 distribution based on the prevalence of clinical signs of trachoma among children ages 1–9
358 years as determined by population-based surveillance prevalence surveys [40]:
 - 359 a) If TF among children 1–9 years old is less than 5.0%, MDA is not required
 - 360 b) If TF among children 1–9 years old is between 5.0% and 9.9%, one year of MDA is
361 recommended, followed by an impact survey at least 6 months following the last MDA

362 c) If TF among children 1–9 years old is between 10% and 29.9%, three years of annual
363 MDA is recommended, followed by an impact survey at least 6 months following the last
364 MDA

365 d) If TF among children 1–9 years old is 30% to 49.9%, five years of annual MDA is
366 recommended, followed by an impact survey at least 6 months following the last MDA

367 e) If TF among children 1–9 years old is above 50%, seven years of annual MDA is
368 recommended, followed by an impact survey at least 6 months following the last MDA.
369 Once TF among children 1–9 years old drops below 5% in a district, the program should
370 wait for two years before conducting a population-based surveillance survey.

371 3. Facial Cleanliness and Environmental Improvement UIG Hygiene promotion and
372 environmental improvement should be conducted in a community so that, at any given time,
373 80 percent of the children in the community will have clean faces.

374 **Outcomes in the control of Trachoma**

375 Whereas³⁸ countries embarked on the rollout of SAFE including mass administration of
376 Azithromycin, only Morocco, Ghana, and Togo were certified by the WHO to have attained the
377 trachoma prevalence elimination threshold as a public health problem [9]. After attaining the
378 respective prevalence elimination threshold, the countries embarked on close surveillance to
379 detect recrudescence of the infection and take appropriate action to control chlamydial re-infection
380 which had also been observed to occur after successful mass drug administration in other
381 countries[9]. However, despite the availability of resources and facilitating contexts, other
382 countries including Tanzania are experiencing both recrudescence and persistence due to wicked
383 implementation problems and hence are indentured to discern the prevailing implementation
384 challenges and contexts timely to make the desired progress.

385 However suggestion to tame the SAFE implementation wicked problems could be through the
386 acquisition of strategies that are based on the SAFE client's needs and their desirables and their
387 participation to inform the development of a novel strategy that overcome the SAFE
388 implementation problems thus enhancing access to the interventions [41]. Thus, it is envisaged
389 that successful implementation of SAFE should not be based researchers preconceived notions
390 of what are the needs and solutions but require systemic solutions that are grounded in the SAFE
391 community's needs, as well as their desirables. Hence such an approach excels because
392 it unleashes innovative solutions based on perceived and felt needs, desires, perceived solutions
393 which is a systemic deployment of design thinking[41].

394 This study aims to employ a design thinking approach in the context of implementation research
395 to design context specific innovative strategies that will enable addressing the implementation
396 problems stalling the implementation of SAFE interventions in the control of Trachoma among
397 nomadic populations in Tanzania thus, achieving the Trachoma prevalence elimination threshold.

398 **Methodology**

399 Implementation research is a scientific undertaking towards solving a problem arising from the
400 implementation process aiming at achieving the desired goal. It is now becoming famous in health
401 and is used to address problems arising from the implementation of clinical, public health, or
402 health system interventions[42]. In that case, the implementation research approach will be proper
403 to disentangle complex factors affecting the implementations and also introduce modified or novel
404 interventions or solutions into the program or the health system.

405 Fundamental to implementation research is to generate an adequate understanding of what, why,
406 and how interventions work in real-world contexts, for this case the Trachoma interventions[43].
407 With such adequate understanding in the real-world setting, we will find and test in this study the
408 effect of novel strategies to improve the performance of the SAFE interventions. Working in a

409 real-world context exactly implies working with communities that are facing SAFE implementation
410 obstacles resulting to Trachoma recrudescence or persistence. Nevertheless, this study will be
411 working with the communities experiencing Trachoma persistence after optimal administration of
412 SAFE and MDA (mass drug administration) as proven effective Trachoma interventions among
413 nomadic population in Manyara region in Tanzania.

414 Additionally, real-world contexts envisage working with the population while focusing on an in-
415 depth understanding of the multilevel contexts which among others includes interaction with both
416 primary and secondary stakeholders, social-cultural, legal, economic, political, and the
417 environment. Others will involve public structures including the health systems, government
418 departments, civil organizations as well as other non-governmental organizations. Furthermore,
419 it emerges that implementation research is focused on optimizing community inputs and
420 involvement to ensure the relevance and effectiveness of the interventions [38]. Such an
421 approach is also identified as community-based participatory research with a strategy to ensure
422 researchers study the correct problems using appropriate methods and problem-relevant
423 interventions or advice suggesting alignment with the appropriate community needs.

424 Implementation research is human-centered and multilevel focusing on people, communities,
425 and health systems supposed to benefit from the SAFE Trachoma interventions[44]. However,
426 to ensure that the communities participates in developing the solutions and adopts the results of
427 the implementation research design thinking approach will be adopted [36]. Design thinking is an
428 approach which is a problem-solving framework with a set of methods starting with empathic
429 understanding of those affected, generation of creative ideas and ultimately testing those ideas
430 and wide-scale adoption [41].

431

432 **Study setting and population**

433 The setting of the study will be a village in Trachoma endemic district experiencing trachoma
434 persistence after an optimal rounds of MDA in Manyara region which will be selected by the
435 National Trachoma Control Program in the Ministry of Health in Tanzania. The study population
436 will be all people in the two selected villages whose population are the SAFE target population
437 since they are all at risk of trachoma infection because of the persistence. Other study population
438 will include, NTD program staff at all levels, Council Health Management Teams, Health Facility
439 leaders, and community leaders as primary stakeholders. The research team will be composed
440 of members with different expertise including ethnographers, social scientist, public health
441 experts, epidemiologists, community development experts and also the national and district
442 Trachoma and NTD coordinators. The study will be implemented in phases iteratively, however,
443 at each phase, its inputs and outputs will be the product of collaborative efforts of the multi-
444 disciplinary team, those affected or at risk of trachoma but also they are targeted for mass drug
445 administration (MDA) whom also will be referred to as the SAFE target population. and a team
446 of multi-experts.

447 **The Approach**

448 Design thinking is a non-linear, open-minded iterative process that our research team will use to
449 understand the SAFE target population, challenge assumptions, redefine problems, and end up
450 with a cutting-edge innovative solution to the SAFE implementation obstacles. Design thinking,
451 brings together what is desirable from a human point of view with what is technologically feasible
452 and economically viable. The pathway to the successful innovative solution is a five-phase journey
453 starting with empathy, then definition followed by ideation, prototype, and finally testing. Finally,
454 the possible intervention will be assessed by the extent of positively it meet needs and desires of
455 SAFE target, its feasibility and its viability. The methodology will iteratively roll over in five-phase,
456 each successive phase building on the preceding phase as follows starting with phase 0:

457 **Phase 0: Acclimatization and rapid assessment**

458 This phase will include forging strong collaborations with stakeholders especially the
459 Trachoma Program at the Ministry of Health, expertise from the Muhimbili University of
460 Health and Allied Sciences (MUHAS), University of Dar es Salaam(UDSM) and the
461 regional teams. It will also involve document reviews, rapid assessments and
462 consultations as follows:

463 a) At onset the three universities and the National Trachoma Control Program of the
464 Ministry of Health will meet discuss and agree on implementation modalities as
465 well as the implementation time-frame and other administration needs. The
466 discussions will also identify expertise and experts who will comprise the field
467 research teams. Participants from MUHAS and UDSM will also have regular
468 meetings and capacity building workshops for the researchers which will focus on
469 implementation research and design thinking for at least one week.

470 b) **Research team** will undertake a rapid assessment to generate a clear
471 understanding of the current magnitude of Trachoma and uptake of the
472 interventions. The phase will also facilitate the identification and clear detailed
473 description of the research problem, the implementation scope and limitations,
474 problem analysis and assessment of already available information, and
475 verification of the villages that will be studied. Data sources for this phase will
476 include reviews of secondary data, grey literature, observations, and a limited
477 collection of qualitative data among stakeholders whose theme will be identified
478 in the process.

479 c) This phase will be culminated with synthesis workshops to enable stakeholders to
480 discuss and deliberate on the results of the rapid assessment. Outcomes will be

481 a common understanding of the challenge to be explored and of the project's
482 scope and further refinements of the methodology, data needs, implementation
483 contexts and tools for the empathy phase.

484 d) This study will utilize design thinking to address this wicked SAFE intervention
485 implementation problems. However, there will also be orienting of all the
486 participating researchers on design thinking to make sure they have uniform
487 understanding and hence common practice. During this phase there will be one
488 week training to enable research team acquire such competencies.

489 d) Implementation in two selected villages will include formation of two field research
490 teams composed of different experts and two research assistants' in each team.
491 It will also prepare relevant data collection tools that are conducive to the research
492 contexts. The initial preparation of tools will depend on the findings from the rapid
493 assessment. Before the beginning of each subsequent phase there will be a
494 workshop to plan the phase, prepare tools and accessing needs as will deem
495 necessary in that particular phase and the phases will be in the following order:

496 **Phase 1: Empathy Phase**

497 Empathy will be putting ourselves in the shoes of the communities experiencing SAFE
498 implementation obstacles (also to be referred to as the SAFE target population) and
499 connecting with how they are feeling about their problem, circumstance, or situation. In this
500 case, our team will put itself in the shoes of the SAFE target population. It will also enable us
501 to connect with how they feel about the problem and the circumstances while putting aside
502 our preconceived knowledge, and own assumptions about the world to gain real insight into
503 the SAFE target population and their needs. Essentially, the empathy phase will

504 predominantly employ ethnography qualitative design [45] that will allow prolonged
505 engagement with the SAFE target population within their communities. Two ethnographers'
506 researchers will lead the research team to undertake the empathic data collection in the
507 respective two study villages focusing on the SAFE target population i.e. what they need, what
508 they want, and how they behave, feel, and think.

509 **Objective:**

510 Undertaking this phase will enable the research team and stakeholders to generate
511 human-centered rich and multidimensional information to understand the SAFE
512 target population and communities. It will enable seeing the real world through the
513 SAFE target population's eyes, and stepping in their shoes to feel what they might
514 be feeling about their problem, circumstance, desires and perceive the solutions
515 from their intuitions.

516 The researchers and data collection team will be primed in advance in the process not to be
517 presumptuous or hasty with SAFE target population perceptions and always operate an
518 ignorant mindset to enable painting a clear picture of the SAFE target populations.

519 Therefore, the two ethnographers in collaboration with the research team and other relevant
520 stakeholders will ensure collection of empathic data relevant to SAFE implementation
521 problems and related contexts. It will focus on the generation of real world adequate data
522 that will include observing SAFE target population and their behaviours in the context of
523 their lives and Trachoma control activities. It will also include interactions and interviews with
524 the SAFE target population using variety of data collection methods. Finally it will involve
525 stepping in the SAFE target populations' shoes in order to eexperience what they
526 experience over the course of implementing the SAFE interventions and the MDA rounds.

527 Various qualitative methods will be used to collect ethnographic data that precisely answers
528 the above questions as follows:

529 1. **Observing SAFE target population.** The research team guided by the ethnographers
530 will also observe the SAFE target population behaviors and interactions related to SAFE
531 in their environments and other contexts. This will also take place in the villages,
532 schools, places of gathering, homes as well as health facilities. The observations will
533 enable research team understand how SAFE target population utilize or practice the
534 SAFE interventions. In addition, it will reveal their needs, pain points, and even
535 unintended uses SAFE interventions.

536

537 2. **Conducting photo (Photovoice)- and/or video-based studies** in SAFE target population
538 natural environments including their interaction sessions with the research team and
539 reflective notes in relation to each photo/video undertaken.

540 3. **Interviewing SAFE target population** – The ethnographers and research team will
541 purposively select individuals from the SAFE target population and then ask for their
542 insights in an intimate setting where they can respond earnestly to open-ended questions.
543 The interviews will be a combination of individual in-depth interviews (IDIs), key informant
544 interviews (KIIs) and focus group discussions (FGDs) depending on the focus and
545 information to be explored. Kiswahili and local language of the SAFE population will be
546 used during the interviews. A translator will be identified to translate interviews for
547 participants who do not speak or understand Kiswahili language.

548 4. **Engaging with the extreme SAFE target population.** – Extreme SAFE target
549 populations will be identified to determine the greatest degrees of SAFE target population
550 needs, problems, problem-solving methods, and persons to establish accurate

551 portraits/profiles of users who will interact with our innovative product. The engagement
552 will comprise of FGDs and/or community workshops with various relevant stakeholders.

553

554 **1.2 Empathy mapping.**

555 This phase follows and compliments the empathy data collection phase and includes defining
556 the problem and problem statement which must be done in a human-centered manner. This
557 phase will help our research team frame and explain the SAFE implementation obstacles that
558 were identified during the empathy phase so that novel solutions for those problems can be
559 created later by the community stakeholders.

560 **Objective:** Empathy mapping will enable the visualization of the empathy data into thoughts,
561 feelings, and actions of the SAFE target population in order give a better understanding of
562 the SAFE target population SAFE experiences and can be used to identify potential areas of
563 improvement by capturing their thoughts, emotions, actions and behaviors through a
564 collaborative visualization of with the SAFE target population.

565 The research team will use the data acquired from the empathy phase to analyze and synthesize
566 it while also assigning it to the relevant quadrant (figure 1) to enable empathy mapping.
567 Eventually, the research team will create an empathy map that will enable one to understand
568 SAFE target population needs by type in the course of developing a deeper understanding of the
569 SAFE target population's needs. The empathy map (see Box 1) will have four major areas in
570 which the research Team will jointly align the empathy results to respective quadrants guided by
571 the following questions:

572 1. What did the SAFE target population say? Data collection will focus on writing down significant
573 quotes and important words said by the respondent.


574 2. What did the SAFE target population do? Data collection will focus on the description of which
575 actions, and cultural norms, practices and behaviors one noticed, inserting pictures or
576 drawings will add value.

577 3. What did the SAFE target population think? Also, data collection will have to dig deeper to
578 answer some of the arising questions.

579 4. How did the SAFE target population feel? What emotions might the SAFE target population
580 be feeling? Data collection should record subtle revelations like body language and their
581 choice of words and tone of voice.

582 The researchers will identify needs based on contradictions between two traits, such as a
583 disconnection between what a user say and what the SAFE target population does. Results from
584 this phase will be passed to the next phase which is **ideation**. Design thinking is an iterative
585 process; it might also require further empathy inputs to make clarifications or complement existing
586 information.

587



588

589 **Phase 2: Define phase**

590 The define phase will follow the empathy phase where the researchers will take on board all
591 information gathered during the empathy phase, analyze, and synthesize it. In addition, the
592 researchers will shape the information into a problem statement which will act as the main guide
593 towards articulating the problem and providing a clear-cut objective to work towards.

594 **Objective:**

595 To provide meaningful, actionable SAFE implementation statements which will steer the
596 research team in the right direction, helping the research team inaugurate efficiently the
597 ideation process to inform the teams and others what can be expected to be achieved as a
598 SAFE implementation innovative solution.

599 The define phase is immediately preceded by the empathy phase where the researchers will have
600 learnt lot about the SAFE target population and most importantly their wants, needs, and pain
601 points. It will include understanding who is experiencing Trachoma and SAFE implementation
602 problems, what are the SAFE implementation and Trachoma problems, what is the periodicity
603 and what are the benefits of solving the problem.

604 Having achieved this, the research team will turn the information from empathy into an actionable
605 problem statement. A problem statement identifies the gap between the current state (i.e. the
606 problem) and the desired state (i.e. the goal) of SAFE interventions among the SAFE target
607 population. The researchers will cast the problem as an unmet need, therefore a good problem
608 statement will be human-centered in this case the SAFE target population and also focus on their
609 needs. Our researchers will frame the problems in actionable format keeping a focus on the SAFE
610 target populations at all times.

611 All problem statements will always be formatted and focused on the SAFE target population
612 perspective. We will avoid statements that start with “we need to...” or “the SAFE target
613 population should”, we will instead concentrate on the SAFE target population’s perspective:
614 “SAFE target population need...”, and should not be too broad

615 An example of casting a statement is.

616 *“I am a young unemployed father of six children trying to get food and living for my family*
617 *from a distant village, but I’m struggling because I work long hours and don’t always have*
618 *time to attend SAFE campaigns and access the interventions. This makes me feel*
619 *frustrated and bad about myself and my family.”*

620 Our research team will then condense all the complex data obtained from the SAFE target
621 population into simple, actionable statements. The research team will use among others a method
622 that will help to condense the information. This study will make use of a way to dig deeper into
623 the problem until a pain point is reached. A workshop of the research team, SAFE target
624 population, and co-opted stakeholders will be held which will condense the data. At this stage,
625 empathy data will have been summarized into meaningful, actionable problem statements. These
626 will be actionable statements that have clues to solutions that will be ready to be moved to the
627 next ideation phase.

628 Phase 3: Ideation phase

629 This phase will follow the define phase and will involve generating a broad set of ideas on a given
630 topic arising from the define phase, in a brainstorming workshop of the research team with no
631 attempt to judge or evaluate them. It will in this case represent an important transitional step from
632 learning about the SAFE target population and the SAFE implementation obstacle, as well as
633 coming up with solutions.

634 **Objective:** To enable research team, SAFE target population, and other stakeholders in
635 a facilitated and judgment-free environment openly generate as many ideas and solutions
636 as possible while addressing each of the selected problem statements from the define
637 phase.

638 In this phase our research team will rephrase the problem statements into a list of questions of
639 “How might we..” Thus, the team will look at each insight statement that the team created in the
640 define phase and rephrase it as questions by adding “How might we” at the beginning.

641 After creating the list of “How might we....” We will generate possible answers which will become
642 a catalyst for the brainstorming workshop. Our research team will compile a list of possible
643 answers and subject each to an ideation technique. The following ideation approaches will be
644 employed to generate possible solutions concerning the stated problem: The team (Research
645 team, SAFE target population, and Co-opted stakeholders) decide on which minimum
646 combination of these techniques will be used given the nature of the problem and also the
647 prevailing contexts. Prioritization or rating of the different problem statements will be

648 3.1 **Brainstorming:** Brainstorming sessions will include researchers, stakeholders,
649 and the SAFE target population. A session will involve verbally bouncing ideas off each
650 other in the workshop in the hopes of finding a blended solution.

651 3.2 **Brain-writing:** Workshop participants will be requested to write down their ideas
652 on the solution of SAFE implementation challenges before passing them on to someone
653 else. For participants who are not able to write, the research assistants will encourage
654 them to speak their ideas and they will help write them down and share with colleagues.
655 The next person reads the ideas and adds their own, and so the process continues until
656 each person’s ideas have done a full rotation. All ideas are then collected and placed in
657 front of the group for discussion.

658 3.3 **Reverse thinking:** Reverse thinking is to flip the SAFE intervention problem on its
659 head and come up with new ideas. Asking such question “how might we make our SAFE
660 interventions more accessible?” could be changed to “how can we make it as difficult as
661 possible for the SAFE target population to access SAFE interventions in this area?” The
662 solutions that will come up from the reverse challenge would help the research team to
663 envision what the opposite might be, leading closer to the solution needed to solve the
664 SAFE intervention problems.

665 Ideation phase is followed by passing the ideas to the prototyping and testing phase and finalizing
666 the tasks. If prototyping and testing phases prove that proposed novel SAFE interventions are
667 implausible we will go back to the ideation phase.

668 **Phase 4: Prototype**

669 At the prototyping phase, filtered problem statements and respective solution from ideation
670 phase will be presented to the SAFE target population in succession to quickly test each design
671 solution to address a defined SAFE implementation problem statement. Instantaneously, it will
672 provide feedback to the research team on what the population think and feel about the new
673 solutions including needed changes. The feedback will then be an important input to the
674 research team in a workshop to revisit and further improve the intervention version or even
675 decide to process another version which might be of higher preference and success among the
676 SAFE target populations.

677 This phase will include conducting workshops that will involve the SAFE target population,
678 researchers, and stakeholders who will be involved interactively to evaluate each version of the
679 proposed innovation product until the acceptable version is reached.

680 **Objective:** Prototyping phase is to turn ideas from the ideation phase into something
681 tangible which can be tested on real users. It is to identify solutions that have a high

682 likelihood of solving SAFE implementation obstacles as being experienced by the SAFE
683 target population.

684 The research team, stakeholders, and the SAFE target population will interact and assess each
685 new version of the innovation which is provided as simple, scaled-down versions of the innovative
686 solution to the prevailing SAFE implementation obstacles. The assessment will include recording
687 observations, judging, and assessing the SAFE target population's general behavior, interactions,
688 and reactions to each version before making the final decision on the innovative solution to be
689 submitted for testing. In addition, it will provide an opportunity for the research team to think
690 critically about the anticipated innovative solutions and also an opportunity to fail quickly and
691 cheaply so that less time and money is invested in a failing idea.

692 The prototype processing team will be composed of the SAFE target population, the research
693 team, and co-opted stakeholders in a workshop setting where they will undertake participatory
694 research that will jointly design and do the prototyping. This phase will enable researchers to get
695 insights about innovative SAFE implementation intervention concerning its usability and SAFE
696 target population experience early in the process.

697 the research team using accruing experiences will decide which of the innovative solutions will
698 be suitable. This stage will assemble the ideas from all or some of the research notes, sketches,
699 pictures, maps, and written versions of the point of view from the earlier phases to concretize it
700 all and test it. Testing each proposed innovation will be based on the responses of the SAFE
701 target population, stakeholders and research team to its suitability and acceptability and decide.
702 In case of failure the process will appreciate that failing is part of learning, and failing is fine and
703 should occur early but it needs to be analyzed to learn from the mistakes.

704 The workshop team envisages producing inexpensive, scaled-down versions of the innovative
705 interventions generated in this phase, and demonstrates the functionality of the ideas before

706 building the final SAFE intervention version. The SAFE target population will be actively involved
707 in this component of designing the innovative intervention.

708 **Phase 5: Test phase**

709 The design thinking process doesn't follow a fixed sequence of steps, but the endpoint is testing
710 phase which is to obtain a problem solution that is desirable, feasible, and viable .

711 **Objective:** To expose the human centered proposed novel intervention to wider group of
712 the SAFE target population and observe how they interact with the product in its current
713 state, and ask for feedback on how the experience and feels in order to confirm that it is
714 feasible.

715 The rationale for conducting the testing on a prototype is to enable an understanding of how the
716 SAFE target population will interact with the selected innovative solution to address the SAFE
717 implementation problems in the local contexts. Our research team will conduct workshop(s),
718 observations and one to one queries with the SAFE target population, leaders and other
719 stakeholders to get their feed back to asses desirability, feasibility and viability of the proposed
720 innovation which will be defined as follows:

- 721 a. Desirability - Proposed solution is desirable if it appeals to the needs, emotions,
722 and behaviors of the SAFE target population.
- 723 b. Feasibility - Is the proposed solution technically possible?
- 724 c. Viability - is the solution self-sustaining?

725 However, when the process is completed a decision will be made to pack and adopt the SAFE
726 intervention prototype for a rollout stage to a wider population at later times. However, in case the
727 SAFE target population does not reveal desirability to the innovation, since design thinking is
728 iterative and non-linear the process will resume the process with a different problem statement or

729 solution ideas from the define or ideation phases. In that case, our research team will go back
730 and re-start the define phase or empathy as the need arises until desirable and acceptable version
731 is obtained.

732 **Data Collection Procedures**

733 the study will employ a combination of qualitative data collection strategies including participant
734 observations, photos/videos, IDI, KII and FGD among the SAFE target populations and related
735 stakeholders. In addition, a series of workshops and community participatory approaches will
736 be conducted at each phase to obtain the required data.

737 Two teams of 2 research assistants, and 1 ethnographer (one team for each study site /village)
738 will be involved throughout the data collection process. In each study site, one overall
739 supervisor will be identified to coordinate and oversee all daily data collection activities including
740 handling logistics, providing feedback on a daily basis, managing collected data and providing
741 support to the team in case of any challenges. The local coordinators from Trachoma control in
742 each study site will link the research team with the local leaders and SAFE target
743 populations as well as to help with the translation during interviews.

744 Standard operating procedures (SOPs) for participant recruitment, data collection and data
745 storage will be developed and implemented throughout the data collection period. All interviews
746 and participants workshops will be audio recorded and notes taken. In addition, notes will be
747 undertaken from participants' observations and reflections from photos/videos as part of data
748 collection.

749 **Capacity building of the research team and research assistants**

750 Before commencement of the study, we will develop training manuals and provide training for
751 research assistants, field supervisors, local coordinators, facilitators and the overall research

752 team. The field team will include only those who demonstrate good performance during the
753 training. During the training, the trainees will be provided with an overview of study and purposes,
754 the design thinking approaches, ethnographic approaches, qualitative data collection and
755 analysis strategies, professional conduct and research ethics, protection of those <18 years and
756 other vulnerable populations, getting accustomed to data collections tools, field logistics, various
757 SOPs for the project and covid-19 prevention protocol.

758 **Data Analysis and interpretation**

759 Audio-recorded Kiswahili interviews and photovoice narratives will be transcribed to text in MS
760 Word computer files and then translated into English. Additionally, all field notes from
761 observations will be typed, and saved in MS Word computer files. We will conduct the initial
762 transcript examination, to obtain the overall sense of the content of responses from participants
763 regarding various issues. Analysis of data will follow qualitative thematic analysis[46] where the
764 transcribed data in MS Word will be imported into NVivo 10 computer-assisted qualitative data
765 analysis software. A codebook will be developed and shared among the research team. The team
766 will discuss, refine and agree on a set of codes relevant to the objectives of the study. This
767 discussion will provide an avenue for the addition of new codes, which may be incorporated into
768 the codebook. The team will use negotiation to resolve disagreements about any issue concerning
769 the identified codes and the coding process. Finally, a common codebook will be developed to
770 facilitate data analysis. Each transcript will be coded to gather material into sub-themes, and
771 finally core themes.

772

773 **Ethical clearance.**

774 This protocol will be submitted to the HKMU Institutional Ethics Review Board requesting a
775 research ethical clearance. Thereafter the clearance will be submitted to the regional and district
776 authorities in which the study sites are located. The authorities will also be requested to give the
777 team permission to undertake the study as well as to introduce the team to the study sites, and
778 health and governance officials. Each participant will be requested to give written consent and
779 assent in a standard format as shown in Appendix A.

780 **Ethical considerations.**

781 The study will not involve any procedures to collect blood or any specimen for laboratory or other
782 procedures hence no pain or injury will be inflicted on the study population. However, this study
783 will use empathy methods that generate multi-dimensional data with the possibility of accessing
784 or infringing on the privacy of individuals and or families. Data collectors will be trained and re-
785 trained to make sure they observe and respect the privacy of the study subjects. The primary data
786 will be kept strictly confidential and delinked from the data sources. Since the information will be
787 used in each subsequent phase of the study, the data will be analyzed and synthesized before
788 submission to the next phase in the process.

789 **References:**

- 790 1. Burton, M.J., *Trachoma: an overview*. British Medical Bulletin, 2007. **84**(1): p. 99-116.
791 2. Solomon, A.W., et al., *The simplified trachoma grading system, amended*. Bull World
792 Health Organ, 2020. **98**(10): p. 698-705.
793 3. Mohammadpour, M., et al., *Trachoma: Past, present and future*. Journal of Current
794 Ophthalmology, 2016. **28**(4): p. 165-169.
795 4. *Trachoma and the safe strategy*. Community eye health, 1999. **12**(32): p. 49-51.

- 796 5. Tian, L. and N.-L. Wang, *Trachoma control: the SAFE strategy*. International journal of
797 ophthalmology, 2018. **11**(12): p. 1887-1888.
- 798 6. Kappagoda, S. and J. Ioannidis, *Prevention and control of neglected tropical diseases:*
799 *Overview of randomized trials, systematic reviews and meta-analyses*. Bulletin of the
800 World Health Organization, 2014. **92**: p. 356-366C.
- 801 7. Wang, N., S. Deng, and L. Tian, *A review of trachoma history in China: research,*
802 *prevention, and control*. Sci China Life Sci, 2016. **59**(6): p. 541-7.
- 803 8. Organization, W.H., *Global Elimination for Trachoma by 2020 (GET 2020)*
804 *in Program for the Prevention of Blindness and Deafness: Alliance for Global Elimination of*
805 *Trachoma*, P.f.t.P.o.B.a.D.A.f.G.E.o. Trachoma, Editor. 1996: Geneva.
- 806 9. Renneker, K.K., et al., *Global progress toward the elimination of active trachoma: an*
807 *analysis of 38 countries*. The Lancet Global Health, 2022. **10**(4): p. e491-e500.
- 808 10. Tsang, K., et al., *Implementing trachoma control programmes in marginalised*
809 *populations in Tanzania: A qualitative study exploring the experiences and perspectives*
810 *of key stakeholders*. PLOS Neglected Tropical Diseases, 2021. **15**(9): p. e0009727.
- 811 11. Organization, W.H., *Ending the neglect to attain the Sustainable Development Goals: A*
812 *road map for neglected tropical diseases 2021–2030*. 2021.
- 813 12. Control, I.C.f.T., *Ending the neglect to attain the Sustainable Development Goals: a road*
814 *map for neglected tropical diseases 2021-2030*, in *Key Tachoma Facts and Statistics*
815 I.C. studies, Editor. 2021, ICTC
- 816 13. The, L., *Neglected tropical diseases: ending the neglect of populations*. The Lancet,
817 2022. **399**(10323): p. 411.
- 818 14. West, S.K., et al., *Infection with Chlamydia trachomatis after mass treatment of a*
819 *trachoma hyperendemic community in Tanzania: a longitudinal study*. Lancet, 2005.
820 **366**(9493): p. 1296-300.

- 821 15. Mwingira, U.J., et al., *Progress of Trachoma Mapping in Mainland Tanzania: Results of*
822 *Baseline Surveys from 2012 to 2014*. *Ophthalmic Epidemiol*, 2016. **23**(6): p. 373-380.
- 823 16. NTDs, E.a.W.F.o., *Tanzania Work Plan FY 2019 Project Year 8 October 2018–*
824 *September 2019*. 2018.
- 825 17. Development, N.T.a.U.S.A.f.I., *Tanzania Work Plan FY 2021 Program Year 3: October*
826 *2020–September 2021*. 2020.
- 827 18. Taylor, H.R., *Doyne Lecture: trachoma, is it history?* *Eye*, 2009. **23**(11): p. 2007-2022.
- 828 19. MABEY, D. and R. BAILEY, *Eradication of trachoma worldwide*. 1999. **83**(11): p. 1261-
829 1263.
- 830 20. Thylefors, B., et al., *Global data on blindness*. *Bulletin of the World Health Organization*,
831 1995. **73**(1): p. 115-121.
- 832 21. Taylor, H.R., *Elimination of blinding trachoma revolves around children*. *The Lancet*,
833 2009. **373**(9669): p. 1061-1063.
- 834 22. Mariotti, S.P., D. Pascolini, and J. Rose-Nussbaumer, *Trachoma: global magnitude of a*
835 *preventable cause of blindness*. 2009. **93**(5): p. 563-568.
- 836 23. Jimenez, V., et al., *Mass drug administration for trachoma: how long is not long enough?*
837 *PLoS neglected tropical diseases*, 2015. **9**(3): p. e0003610-e0003610.
- 838 24. Desmond, N., et al., *Acceptability of azithromycin for the control of trachoma in Northern*
839 *Tanzania*. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 2005.
840 **99**(9): p. 656-663.
- 841 25. Mabey, D. *Trachoma: Recent Developments*. in *Hot Topics in Infection and Immunity in*
842 *Children IV*. 2008. New York, NY: Springer New York.
- 843 26. Harding-Esch, E.M., et al., *Trachoma Prevalence and Associated Risk Factors in The*
844 *Gambia and Tanzania: Baseline Results of a Cluster Randomised Controlled Trial*.
845 *PLOS Neglected Tropical Diseases*, 2010. **4**(11): p. e861.

- 846 27. Chaudhry, I.A., *Eradicating blinding trachoma: What is working?* Saudi J Ophthalmol,
847 2010. **24**(1): p. 15-21.
- 848 28. Bero, B., et al., *Prevalence of and Risk Factors for Trachoma in Oromia Regional State*
849 *of Ethiopia: Results of 79 Population-Based Prevalence Surveys Conducted with the*
850 *Global Trachoma Mapping Project.* Ophthalmic Epidemiology, 2016. **23**(6): p. 392-405.
- 851 29. Burton, M.J., et al., *The Long-Term Natural History of Trachomatous Trichiasis in The*
852 *Gambia.* Investigative Ophthalmology & Visual Science, 2006. **47**(3): p. 847-852.
- 853 30. Grassly, N., et al., *The Natural History of Trachoma Infection and Disease in a Gambian*
854 *Cohort with Frequent Follow-Up.* PLoS neglected tropical diseases, 2009. **2**: p. e341.
- 855 31. Ramadhani, A.M., et al., *Blinding Trachoma: Systematic Review of Rates and Risk*
856 *Factors for Progressive Disease.* PLoS Negl Trop Dis, 2016. **10**(8): p. e0004859.
- 857 32. Al-Khatib, T., et al., *Trachoma: The Last Decade?* Ophthalmic Epidemiology, 2023.
858 **30**(6): p. 541-543.
- 859 33. Control, I.C.o.T., *Key Trachoma Facts and Statistics in WHO Weekly Epidemiological*
860 *Records* ICTC, Editor. 2023, ICTC: Geneva
- 861 34. Grassly, N.C., et al., *The Natural History of Trachoma Infection and Disease in a*
862 *Gambian Cohort with Frequent Follow-Up.* PLOS Neglected Tropical Diseases, 2008.
863 **2**(12): p. e341.
- 864 35. Hu, V.H., et al., *Epidemiology and control of trachoma: systematic review.* Tropical
865 *medicine & international health : TM & IH*, 2010. **15**(6): p. 673-691.
- 866 36. Edwards, T., et al., *Risk factors for active trachoma and Chlamydia trachomatis infection*
867 *in rural Ethiopia after mass treatment with azithromycin.* 2008. **13**(4): p. 556-565.
- 868 37. Mahande, M.J., H.D. Mazigo, and E.J. Kweka, *Association between water related factors*
869 *and active trachoma in Hai district, Northern Tanzania.* Infectious Diseases of Poverty,
870 2012. **1**(1): p. 10.

- 871 38. Maritim, P., et al., *Factors shaping the implementation of the SAFE strategy for*
872 *trachoma using the Consolidated Framework for Implementation Research: a systematic*
873 *review*. *Global Health Action*, 2019. **12**(1): p. 1570646.
- 874 39. Paul Emerson, L.F., Robin Bailey and David Mabey, *Implementing the SAFE Strategy*
875 *for Trachoma Control:*
876 *A Toolbox of Interventions for Promoting Facial Cleanliness and Environmental Improvement*, in
877 *The Carter Center, T.C.C.T.C. Program, Editor. 2006.*
- 878 40. International Trachoma Initiative, *Mass Drug Administration: Zithromax® Supply Chain*
879 *Assessment Tool* in *Zithromax® Supply Chain Assessment Tool*, ITI, Editor. 2019,
880 International Trachoma Initiative.
- 881 41. Brown, T. and J. Wyatt, *Design Thinking for Social Innovation*. *Stanford Social*
882 *Innovation Review*, 2009. **8**(1): p. 31-35.
- 883 42. Peters, D., et al., *Implementation research: What it is and how to do it*. *BMJ (Clinical*
884 *research ed.)*, 2013. **347**: p. f6753.
- 885 43. Huang, T.T.K., et al., *Design Thinking to Improve Implementation of Public Health*
886 *Interventions: An Exploratory Case Study on Enhancing Park Use*. *Design for health*
887 (Abingdon, England), 2018. **2**(2): p. 236-252.
- 888 44. Huang, T. and A. Yaroch, *A Public-Private Partnership Model for Obesity Prevention*.
889 *Preventing chronic disease*, 2009. **6**: p. A110.
- 890 45. Sangasubana, N., *How to Conduct Ethnographic Research*. *The Qualitative Report*,
891 2011. **16**: p. 567-573.
- 892 46. Clarke, V. and V. Braun, *Teaching thematic analysis: Overcoming challenges and*
893 *developing strategies for effective learning*. *The Psychologist*, 2013. **26**: p. 120-123.
894